Antibe Therapeutics Inc(Pre-Merger) ATBPF

Zacks Investment Research - ATE upgareded to $28/share

[Alex1967]

Antibe continues to execute on its strategy as it moves otenaproxesul toward initiation ofa global Phase 3 program. We anticipate an IND filing and an ‘End of Phase 2’meeting to occur during the first half of 2021 such that the first Phase 3 clinical trial can initiate by the end of the second quarter of 2021, withsubsequent trials initiating over the subsequent months. We are looking forward to continued updates as the company meets with regulatory authorities in preparation for the Phase 3 program. We have adjusted our model to account for the recent 1:10 share consolidation and our valuation is CAD$28.00 per share

[Pandora]

Did they put a time frame of years for that $28/share? Just wondering if it will be in my lifetime or if it's like Knight Therapeutics (T.GUD) where the CEO Goodman says "plan on it for your grandkids at the earliest not for yourself." At my age I decided to get out of that one - that was about 3 years ago when it was in the $8 range - now just under $5.50. I would hope ATE has a

[MrMugsy]

Let's put it this way Pandora ... Analysts have been saying $43 for PRN for over a year.  Still at $24.  But, it was at $6 when the shelf prospectus was initiated.  So, I'm going to say that you have a better chance of seeing that share price if we're taken out and not before. Hope that helps!

[Alex1967]

No time frame. "Based on our probability adjusted DCF model that takes into account potential future revenues from otenaproxesul, ATE.V is valued at CAD$28.00 per share. This model is highly dependent upon continued clinical success of otenaproxesul and will be adjusted accordingly based upon future clinical results and the company’s execution"

[Actuarial]

$28 is a conditional and discounted present value - conditional on successful FDA approval. In another word, it is the valuation as of today. When the time getting close to commercial launch, SP would be much higher than $28. Assume the discount rate being 5%, commercial launch date 2023, then the SP = $28 * 1.05^ (2023-2020) = $32.41. The higher discount rate, the higher SP would be when the time

[StockGuy2136]

LMAO

[TriumphSpitSix]

I've made this point before also. It's not a 12-month price target. It should be $28/share TODAY.

[Actuarial]

Exactly. $4 = $28 * 14.29% => the buyers' current view on probability of getting FDA approval is around 14.29%, which is severe underestimated IMO. GLTA!

[Fintech99]

Don't you mean 600% from the current share price of $4 (CAD)? $28 - $4 = $24 difference / $4 = 6 x 100% = 600%?